Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M2SR Prime-Boost Influenza Vaccine in Children
NCT03553940Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2018
- Primary completion
- Aug 2020
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in influenza comparing M2SR Prime + QIV Boost with Placebo Prime + QIV Boost (2 arms). Primary endpoints: Adverse Events of Special Interest, New Onset Chronic Medical Conditions and 3 more. Started Aug 2018; status: completed.
02
Drugs
M2SR H3N2 influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03553940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553940.